Literature DB >> 18761212

Dasatinib-induced lupus.

Delphine Rea, Anne Bergeron, Claire Fieschi, Djaouida Bengoufa, Eric Oksenhendler, Hervé Dombret.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18761212     DOI： 10.1016/S0140-6736(08)61295-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Molecularly and clinically related drugs and diseases are enriched in phenotypically similar drug-disease pairs.

Authors:  Ingo Vogt; Jeanette Prinz; Mónica Campillos
Journal:  Genome Med       Date:  2014-08-17       Impact factor: 11.117

Review 2.  Metabolism considerations for kinase inhibitors in cancer treatment.

Authors:  Derek R Duckett; Michael D Cameron
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10       Impact factor: 4.481

3.  Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.

Authors:  Charles Chuah; Junia V Melo
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

4.  Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.

Authors:  Xiaohai Li; Yuanjun He; Claudia H Ruiz; Marcel Koenig; Michael D Cameron; Tomas Vojkovsky
Journal:  Drug Metab Dispos       Date:  2009-03-12       Impact factor: 3.922

5.  Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.

Authors:  Marie P Shieh; Masato Mitsuhashi; Michael Lilly
Journal:  Clin Med Insights Oncol       Date:  2011-06-23

6.  Autophagy protects against dasatinib-induced hepatotoxicity via p38 signaling.

Authors:  Xiaochun Yang; Jincheng Wang; Jiabin Dai; Jinjin Shao; Jian Ma; Chao Chen; Shenglin Ma; Qiaojun He; Peihua Luo; Bo Yang
Journal:  Oncotarget       Date:  2015-03-20

7.  ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.

Authors:  Mariko Yoshimura; Kensuke Kojima; Rika Tomimasu; Noriyasu Fukushima; Shinichiro Hayashi; Eisaburo Sueoka; Shinya Kimura
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

8.  Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib.

Authors:  David Sanford; Maria MacDonald; Michael Nicolle; Anargyros Xenocostas
Journal:  Hematol Rep       Date:  2014-06-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.